13F Pro Quality Score
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $11.3M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Reported revenue, net income and operating margin by fiscal year, from Basel Medical Group Ltd's annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 20-F/A | $11.3M | $-10.6M | -97.7% |
| FY 2024 | 20-F/A | $10.1M | $2.1M | 23.9% |
Basel Medical Group Ltd (BMGL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BMGL is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $11.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Basel Medical Group Ltd reports quarterly revenue of $11.3M, net income of $-10.6M, an operating margin of -97.7%. BMGL trades on the Nasdaq exchange and files with the SEC under CIK 2004489. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Basel Medical Group Ltd directly from SEC EDGAR.